logo.png
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
April 23, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1...
logo.png
Roche purchases shares in tender offer for GenMark Diagnostics, Inc.
April 22, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Basel, 22 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics, Inc. today announced that Roche’s wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all...
Roche reports solid results in the first quarter of 2021
April 21, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Basel, 21 April 2021 Group sales increase 3%1 at constant exchange rates (CER); 1% decline in Swiss francs, as a result of the appreciation of the Swiss franc Pharmaceuticals Division sales:...
Roche fait état de solides résultats au premier trimestre 2021
April 21, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Bâle, le 21 avril 2021 Le chiffre d’affaires consolidé progresse de 3%1 à taux de change constants (TCC), mais s’inscrit en baisse de 1% en francs suisses en raison de...
Roche mit soliden Ergebnissen im ersten Quartal 2021
April 21, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Basel, 21. April 2021 Konzernverkäufe steigen währungsbereinigt um 3%1 und sinken in Schweizer Franken um 1% aufgrund der Stärke des Schweizer FrankensVerkäufe der Division Pharma: Anhaltend...
logo.png
New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis
April 16, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE studyOCREVUS significantly...
logo.png
Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
April 15, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
More than twice as many babies (61% vs. 29%) were able to sit without support for at least five seconds after 24 months compared to 12 months of treatmentEvrysdi increased survival and reduced need...
logo.png
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
April 13, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
●  Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment Basel, 13 April 2020 - Roche (SIX:...
logo.png
Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
April 12, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
Among individuals who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom durationIn a cohort of...
logo.png
New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio
April 08, 2021 01:00 ET | F. Hoffmann-La Roche Ltd
EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)OCREVUS data show its consistent benefit on slowing disease progression in...